Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Rettenmaier

Undersea and Hyperbaric Medicine Fort Wayne, IN Doctor of Osteopathy

NPI 1871593418 CMS profile 39816

1355 Getz Rd Ste C, Fort Wayne, IN 46804

Open in the dashboard

General payments

$3,114

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Rettenmaier of Fort Wayne, IN is reported in the CMS Open Payments database as having received $3,114 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $356 11
2024 General $187 4
2023 General $145 4
2022 General $598 56
2021 General $388 54
2020 General $293 27
2019 General $1,148 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Rettenmaier
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Philip Rettenmaier were reported at $356. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Philip Rettenmaier Undersea and Hyperbaric Medicine median Middle half National median
2019 $1,148 $201 $85–$538 $163
2020 $293 $84 $31–$222 $114
2021 $388 $138 $52–$383 $132
2022 $598 $135 $51–$385 $149
2023 $145 $143 $75–$442 $160
2024 $187 $178 $80–$442 $164
2025 $356 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,105 163 payments
  2. Organogenesis Inc. $950 18 payments
  3. Paratek Pharmaceuticals, Inc. $156 3 payments
  4. KCI USA, Inc $147 4 payments
  5. AbbVie, Inc. $123 2 payments
  6. Reprise Biomedical, Inc. $95 1 payment
  7. Boston Scientific Corporation $92 1 payment
  8. Tactile Systems Technology Inc $66 3 payments
  9. E.R. Squibb & Sons, L.L.C. $60 1 payment
  10. Solventum Corporation $55 1 payment
  11. Other $264 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,975 208 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $110 1 payment
  3. Long term medical supply or device loan $30 1 payment
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL Pharma Products $403 50 payments
  2. Apligraf Wound Care $351 4 payments
  3. Santyl $339 60 payments
  4. Puraply $286 8 payments
  5. COLLAGENASE SANTYL Pharma Product $250 46 payments
  6. Apligraf Podiatry $235 2 payments
  7. Puraply/Affinity/NuTech $235 2 payments
  8. Dermagraft $235 2 payments
  9. NUZYRA $156 3 payments
  10. VAC VERAFLO $100 1 payment
  11. Other $1,425 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

40

Prescriptions dispensed, refills included

Drug cost

$670

Paid at the pharmacy, in all

Branded share of claims

0%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 13 $537
Triamcinolone Acetonide Generic 16 $76
Levofloxacin Generic 11 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$34,624

Medicare's payments for the services billed

Medicare patients

97

Average age 71

Services billed

682

40 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Diabetes 55%
Arthritis 51%
Ischemic heart disease 46%
Heart failure 43%
Atrial fibrillation 37%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record